RxDoctor Payments Data

Philomena Ukwade, MD

Internal Medicine · Friendswood, TXNPI 1972593358

Payments from drug & device makers

$2,986in general payments, 2019–2025

Across 158 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$677
  • Lilly USA, LLC$534
  • Novo Nordisk$284
  • Amgen$208
  • Boehringer Ingelheim$193
  • Astellas Pharma US Inc$137
  • plus $953 from 22 others

What the payments were for

  • Food & beverage$2,875100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,986 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$71,865
Medicare patients
118
Services billed
967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin67$72,560
FarxigaDapagliflozin Propanediol64$65,746
MounjaroTirzepatide50$55,853
OzempicSemaglutide56$55,210
Xigduo XrDapaglifloz Propaned/Metformin32$32,905
EliquisApixaban21$28,849
TrulicityDulaglutide24$22,697
XareltoRivaroxaban13$18,037
TradjentaLinagliptin13$12,175
MyrbetriqMirabegron13$11,020
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,191
Venlafaxine Hcl ErVenlafaxine Hcl17$4,272
Rosuvastatin Calcium331$3,820
Atorvastatin Calcium440$3,620
Losartan Potassium255$3,040

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$193$84,73580 claims
Lilly USA, LLCMounjaro, Trulicity$534$78,55074 claims
AstraZenecaFarxiga$677$65,74664 claims
Novo NordiskOzempic$284$55,21056 claims
PfizerEliquis$132$28,84921 claims
Johnson & JohnsonXarelto$121$18,03713 claims
Astellas Pharma US IncMyrbetriq$137$11,02013 claims
GSKTrelegy Ellipta$22$8,19111 claims
AbbVieSynthroid$11$1,03629 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Friendswood

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →